Detalhe da pesquisa
1.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Lancet
; 402(10411): 1449-1458, 2023 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696275
2.
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Ophthalmology
; 128(4): 576-586, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32882310
3.
PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Retina
; 41(1): 144-155, 2021 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32134802
4.
Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor ß for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
Ophthalmology
; 127(2): 211-220, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791663
5.
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Ophthalmology
; 126(8): 1155-1170, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30905643
6.
A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Graefes Arch Clin Exp Ophthalmol
; 255(3): 463-473, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27632215
7.
9.
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Eye (Lond)
; 37(17): 3551-3557, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964259
10.
Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Ophthalmol Retina
; 7(7): 573-585, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906177
11.
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
Retina
; 31(5): 915-23, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21487341
12.
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema.
Ophthalmol Sci
; 1(3): 100040, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36247818
13.
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
JAMA Ophthalmol
; 138(9): 955-963, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32729888
14.
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
JAMA Ophthalmol
; 138(9): 964-972, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32729897
15.
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
Ophthalmol Retina
; 4(7): 673-688, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199866
16.
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
J Ocul Pharmacol Ther
; 34(10): 700-709, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30412448
17.
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Eye (Lond)
; 37(17): 3705, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237234